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Abstract 1 
Background & Aims: Extrahepatic cholangiocarcinoma (EHCC) is very difficult to 2 
diagnose, and has a poor prognosis. Novel EHCC biomarkers for early detection, 3 
diagnosis and treatment selection are needed. This study was designed to identify 4 
and validate novel biomarkers using mass spectrometry (MS)-based proteomics 5 
approaches. 6 
Methods: I analyzed a discovery set of formalin-fixed paraffin-embedded (FFPE) 7 
tissues of 7 stage I and 7 stage IV EHCC, and 7 controls employing shotgun mass 8 
spectrometry. Semi-quantitative spectral counting was used to compare the 9 
resulting proteome profiles. Selected candidates were verified by quantitative 10 
analysis using scheduled selected reaction monitoring-based MS. 11 
Immunohistochemical analysis employed a validation set of 165 cases. 12 
Results: In total, 1,992 proteins were identified from the discovery set, including 13 
136 proteins overexpressed in EHCC by spectral counting. Verification of 58 14 
selected proteins by quantitative analysis revealed 11 overexpressed proteins in 15 
EHCC. Immunohistochemical validation showed positive rates of S100P (84%), 16 
CEAM5 (75%), MUC5A (62%), OLFM4 (60%), OAT (42%), CAD17 (41%), FABPL 17 
(38%), AOFA (30%), K1C20 (25%) and CPSM (22%). 18 
Conclusions: I identified 10 proteins associated with EHCC using MS-based 19 
proteomic approaches from archived FFPE tissues. These proteins are potential 20 
new targets for early diagnostic biomarkers and therapy.21 
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Abbreviations: 22 
ACTB, actin, beta; AOFA, amine oxidase [flavin-containing] A; CAD17, 23 
cadherin-17; CE, collision energy; CEA, carcinoembryonic antigen; CEAM5, 24 
carcinoembryonic antigen-related cell adhesion molecule 5; CPSM, 25 
carbamoyl-phosphate synthase [ammonia]; EHCC, extrahepatic 26 
cholangiocarcinoma; FABPL, fatty acid-binding protein, liver; FFPE, 27 
formalin-fixed paraffin-embedded; HMCS2, hydroxymethylglutaryl-CoA 28 
synthase; ISIS, in-sample internal standard; JSBS, Japanese Society of Biliary 29 
Surgery; K1C20, keratin, type I cytoskeletal 20; LC, liquid chromatography; LMD, 30 
laser micro dissection; MS, mass spectrometry; MS/MS, tandem mass 31 
spectrometry; MUC5A, mucin-5AC; NSAF, normalized spectral abundance factor; 32 
OAT, ornithine aminotransferase; OLFM4, olfactomedin-4; Rsc, protein ratio from 33 
spectral counting; S100P, protein S100-P; SRM, selected reaction monitoring; 34 
sSRM, scheduled SRM, UICC; International Union Against Cancer   35 
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Introduction 36 
Cholangiocarcinomas, malignant tumors arising from bile ducts, account for 3% of 37 
all gastrointestinal cancers,1 and are classified according to their anatomic 38 
location as intrahepatic and extrahepatic cholangiocarcinomas (EHCC). EHCC is 39 
very difficult to diagnose and has a poor prognosis which has improved only 40 
marginally over the past 30 years.2 Although complete surgical resection is the 41 
only opportunity for cure, the 5-year survival rate after complete resection is 42 
39.1% for hilar EHCC, and 44.0% for distal EHCC.3 Factors responsible for these 43 
poor outcomes of EHCC include the limitations of diagnostic modalities, with 44 
currently available biomarkers lacking sensitivity and specificity. The 45 
sensitivities of clinically-used markers such as carcinoembryonic antigen (CEA) 46 
and carbohydrate antigen 19-9 are 30-70% and 53-85%, respectively.4-9 47 
Furthermore, these markers can be elevated in other cancers10 and in cholestasis 48 
without malignancy.11 Therefore, novel biomarkers for early detection, diagnosis 49 
and treatment selection are needed. 50 
Mass spectrometry (MS) is reportedly valuable in both preclinical and clinical 51 
research12, 13 as well as for biomarker discovery.14, 15 Shotgun proteomics is a 52 
method of identifying proteins in complex mixtures using liquid chromatography 53 
(LC) and MS in combination to provide global proteome profiles.16, 17 Meanwhile, 54 
targeted proteomics based on selected reaction monitoring (SRM) is an 55 
appropriate method for accurate identification and quantitation of proteins of 56 
interest.18, 19 57 
Identification of scarce biomarkers in serum and plasma remains challenging 58 
because of the complexity and wide dynamic range characterizing such samples.20 59 
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Cancer-specific proteins exist at high concentrations within tumor tissues as 60 
compared with other samples. Thus, cancerous tissue itself is an important source 61 
for biomarker discovery. However, sampling of unfixed tissue must be carried out 62 
prospectively over several years to collect enough cases for research purposes. 63 
Formalin-fixed paraffin-embedded (FFPE) tissues have, however, been 64 
extensively collected and stored in hospitals for various periods of time. FFPE 65 
tissues are readily available, pathologically well-defined, and include all stages of 66 
cancer, even for rare diseases. The use of FFPE tissue for proteomic analysis has 67 
long been limited to immunohistochemistry, due to formalin-induced covalent 68 
cross-linking, which renders proteins relatively insoluble and unsuitable for 69 
extraction.21, 22 However, newly developed technology has made it possible to 70 
efficiently extract proteins from FFPE tissues, thereby allowing proteomic 71 
analysis.23 Although successful MS analysis of FFPE tissue has recently been 72 
reported,24-26 there are no reports of biomarker discovery from archived FFPE 73 
samples of EHCC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              74 
  I conducted a large-scale retrospective proteomic study to identify novel 75 
proteins overexpressed in EHCC employing shotgun and targeted proteomics of 76 
FFPE tissues. I further validated the candidate proteins by immunohistochemical 77 
analysis and identified 10 proteins overexpressed in EHCC.  78 
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Materials and Methods 79 
Tissues 80 
I retrospectively retrieved EHCC samples from patients undergoing resection 81 
between 1998 and 2008 at Tohoku University Hospital. Those given neoadjuvant 82 
therapy were excluded. Intrahepatic cholangiocarcinoma, carcinoma of the 83 
gallbladder and carcinoma of the papilla of Vater cases were also excluded. 84 
Non-cancerous bile duct tissues were obtained from pancreatic cancer patients 85 
with pancreaticoduodenectomy. In total, 186 FFPE tissues, 165 EHCCs and 21 86 
non-cancerous bile ducts, were examined. Before analysis, hematoxylin and eosin 87 
stained sections from each sample were evaluated by a pathologist. The suitability 88 
of study inclusion was determined. According to the Classification of Biliary Tract 89 
Carcinoma by Japanese Society of Biliary Surgery (JSBS),27 the numbers of stage 90 
I, II, III and IV EHCC tissues were 12, 37, 50 and 66, respectively. For MS 91 
analyses, a discovery set of 21 samples from stage I EHCC (n = 7), stage IV EHCC 92 
(n = 7), and non-cancerous bile duct tissues (n = 7) was used. JSBS stage I 93 
corresponds to stage IA in International Union Against Cancer (UICC) 6th edition, 94 
while JSBS stage IV includes stages IIA and IIB in UICC. The remaining 165 95 
samples, 151 EHCCs and 14 non-cancerous bile ducts, served as a validation set. 96 
Informed consent was obtained from individual patients. This study was approved 97 
by the Tohoku University Ethics Committee. The study design and composition of 98 
the discovery and validation sets are shown in Figure 1. 99 
Laser Micro Dissection (LMD) and protein extraction 100 
Cancerous lesions and non-cancerous bile duct epithelium were identified on 101 
serial, hematoxylin and eosin-stained sections. For proteomic analysis, 10-µm 102 
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sections prepared from the same tissue block were attached to DIRECTORTM 103 
slides (Expression Pathology, Gaithersburg, MD, USA), de-paraffinized three 104 
times with xylene for 5 min, rehydrated with graded ethanol solutions and 105 
distilled water, and then stained with hematoxylin.28 Stained, uncovered slides 106 
were air dried and about 30,000 cells (8 mm2) were collected into the cap of a 107 
0.2-mL PCR tube using Leica LMD6000 (Leica Microsystems GmbH, Wetzler, 108 
Germany). Peptides were extracted using a Liquid TissueTM MS Protein Prep kit 109 
(Expression Pathology)23 according to the manufacturer’s instructions. 110 
Exploratory shotgun analysis 111 
1. LC-tandem mass spectrometry (MS/MS) 112 
Peptide-mixture samples processed from FFPE tissues were used for LC-MS/MS 113 
employing a Finnigan LXQ linear ion-trap mass spectrometer (Thermo Fisher, CA, 114 
USA).28 A capillary reverse phase LC-MS/MS system (ZAPLOUS SystemTM; AMR, 115 
Tokyo, Japan), comprised of a Paradigm MS4 (Michrom BioResources, CA, USA), 116 
an HTC PAL autosampler (CTC Analytics, Zwingen, Switzerland) and Finnigan 117 
LXQ linear ion-trap mass spectrometer, was equipped with an ADVANCE 118 
nanospray ionization source (Michrom BioResources). The Liquid TissueTM 119 
solvents were evaporated and peptides were redissolved with graded water 120 
containing 0.1% trifluoroacetic acid and 2% acetonitrile (eluent C). Samples were 121 
automatically injected into a peptide L-trap column (CERI, Tokyo, Japan) 122 
attached to an injector valve for desalinating and concentrating peptides. After 123 
washing the trap with eluent C, the peptides were loaded into a separation 124 
capillary reverse phase column (MAGIC C18AQ packed with gel particles of 3 µm 125 
in diameter and 100 Å pore size, 150×0.1 mm, Michrom BioResources) by 126 
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switching the valve. The eluents used were: A, 98% H2O/2% acetonitrile/0.1% 127 
formic acid; and B, 10% H2O/90% acetonitrile/0.1% formic acid. The column was 128 
developed at a flow rate of 500 nL/min with the concentration gradient of 129 
acetonitrile: from 5% B to 45% B in 100 min, then from 45% B to 95% B in 1 min, 130 
sustaining 95% B for 9 min, from 95% B to 5% B in 1 min, and finally 131 
re-equilibrating with 5% B for 9 min. The spray voltage was set between 1.5 and 132 
1.6 kV. The ion transfer tube temperature was 200 °C. No sheath or auxiliary gas 133 
was used. The mass spectrometer was operated in the m/z range of 450–2,000 in 134 
the data dependent mode to acquire one full scan mass spectrum and, then, 135 
MS/MS spectra of the three most intense peaks. The full MS scans were acquired 136 
in profile mode and MS/MS scans were acquired in centroid mode. The specific 137 
m/z value of the peptide fragmented by collision activated dissociation was 138 
excluded from reanalysis for 3 min using the dynamic exclusion option. 139 
2. Data analysis and protein identification 140 
Mascot software (version_2.2.03, Matrix Science, London, UK) was used for a 141 
database search against Homo sapiens entries in the Swiss-Prot 55.6 database 142 
(20,009 entries). Peptide and fragment mass tolerances were 2.0 Da and 1.0 Da, 143 
respectively, and trypsin specificity was applied with a maximum of 2 missed 144 
cleavages. Methionine oxidation, and N-formylation including formyl (K), formyl 145 
(R) and formyl (N-terminus), were allowed as variable modifications. A P-value 146 
less than 0.05 was considered to be significant in protein identification. Reported 147 
results were obtained from triplicate LC-MS runs for each sample. 148 
3. Semi-quantitative comparison using spectral counting 149 
To compare protein expressions across all tissue samples, I used the spectral 150 
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counting method. The number of peptide spectra with high confidence (Mascot ion 151 
score, P < 0.05) served as the spectral count value. Fold changes in the expressed 152 
proteins on a base-2 logarithmic scale were calculated using the protein ratio from 153 
spectral counting (Rsc).29 Relative abundances of identified proteins were also 154 
obtained by applying the normalized spectral abundance factor (NSAF).30 155 
Candidate proteins differing between groups were chosen so that their Rsc would 156 
satisfy the ≥ 1 criterion, corresponding to a fold change ≥ 2, and with statistical 157 
significance at P < 0.05 by the G-test.31, 32 158 
Targeted verification analysis by SRM mass spectrometry 159 
SRM-based MS analysis was conducted using a discovery set. Proteins for SRM 160 
verification were mainly selected from among biomarker candidates identified by 161 
shotgun analysis and spectral counting. Furthermore, several proteins that were 162 
not overexpressed in EHCC in my shotgun analysis but were previously reported 163 
to be potential biomarkers were added to the SRM list for verification.33-36  164 
An LC-MS/MS system was comprised of a Paradigm MS4 (Michrom 165 
BioResources) connected to a 4000 QTRAP hybrid system (AB Sciex, CA, USA) 166 
operating in positive ion mode.18 A 2.5-µL aliquot of each sample was desalinated 167 
on line with an L-trap micro cartridge 0.3 mm in length (CERI) fitted to the 168 
autosampler HTS-PAL injector valve (CTC analytics), which had been 169 
pre-equilibrated with eluent C. After switching the valve, peptides were loaded on 170 
an L-column (0.1 × 150 mm, 3 µm; CERI) for separation. Peptides were eluted 171 
from the column with a linear gradient from 5% B to 55% B in 45 min, then from 172 
55% B to 95% B in 1 min, sustaining 95% B in 3 min, from 95% B to 5% B in 1 min, 173 
finally re-equilibrating with 5% B for 10 min at a flow rate of 0.5 µL/min. The LC 174 
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eluent was subjected to positive ion nanoflow analysis using an AD-H6 nano spray 175 
interface (AMR).  176 
The operation conditions were as follows: ionspray voltage 2,200V; curtain gas 177 
pressure, 0 psi; nebulizer gas and heating gas pressure (GS1 and GS2), 0 psi. The 178 
source temperature was set at 150 °C. For all SRM studies, quadrupoles were 179 
operated under conditions of unit/unit resolution, and the collision energy (CE) 180 
was determined using the equation: CE = 0.044 × m/z + 6 for doubly-charged 181 
precursor ions. The scheduled SRM (sSRM) mode was utilized in this study, with 182 
the sSRM detection window set at 180 sec. 183 
Individual peptides for monitoring were determined empirically using data 184 
obtained in the shotgun experiments. For each peptide, 4 SRM transitions were 185 
selected to increase the reliability of the quantification values.37 Since 186 
fragmentation profiles in the LXQ generally differ from those in the 4000 QTRAP, 187 
SRM transitions for candidate peptides were evaluated preliminarily using a 4000 188 
QTRAP instrument by measuring the project control (mixtures of equal aliquots of 189 
all patient samples) to confirm sufficient sensitivity and the retention time. 190 
Transitions stably detected by preliminary analysis were adopted for an SRM 191 
assay. The peptide AGFAGDDAPR (m/z 488.7) is a doubly-charged actin, beta 192 
(ACTB) peptide and its specific SRM transition to the singly charged fragment 193 
(m/z 630.3) served as the internal standard.38 This internal standard is referred to 194 
as the in-sample internal standard (ISIS) since ACTB is a housekeeping protein.39 195 
Peak areas of each transition were normalized using the equation: Normalized 196 
peak area = peak area × (500,000/peak area of 488.7/630.3). The averaged values 197 
of stage I EHCC and stage IV EHCC based on triplicate runs were each compared 198 
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to those of non-cancerous bile duct tissues, and an expression difference of at least 199 
2-fold was defined as overexpression. 200 
Immunohistochemistry 201 
A validation set was employed. Sections (2-µm thick) after de-paraffinization with 202 
xylene were rehydrated with a graded ethanol series and distilled water. Protein 203 
S100-P (S100P) (HPA019502, Sigma, MO, USA), carcinoembryonic 204 
antigen-related cell adhesion molecule 5 (CEAM5) (HPA019758, Sigma), 205 
mucin-5AC (MUC5A) (OBT1746, AbD Serotec, Oxford, UK), olfactomedin-4 206 
(OLFM4) (ab96280, abcam, MA, USA), cadherin-17 (CAD17) (HAP023616, Sigma), 207 
keratin, type I cytoskeletal 20 (K1C20) (HPA027236, Sigma) , and 208 
carbamoyl-phosphate synthase [ammonia] (CPSM) (ab54586, abcam) 209 
immunostaining was achieved by heating slides in an autoclave at 120°C for 5 210 
min in citrate acid buffer (10 mM citric acid, pH 6.0). Similarly, antigen retrieval 211 
for fatty acid-binding protein, liver (FABPL) (ab82157, abcam) was performed by 212 
heating slides in a microwave oven for 15 min in a citric acid buffer. No antigen 213 
retrieval was carried out for ornithine aminotransferase (OAT) (HPA040098, 214 
Sigma) or amine oxidase [flavin-containing] A (AOFA) (NBP1-19796, Novus 215 
Biologicals, CO, USA). The dilutions of primary antibodies were as follows: S100P, 216 
1: 3000; CEAM5, 1: 40; MUC5A, 1: 50; OLFM4, 1: 100; CAD17, 1: 1500; K1C20, 1: 217 
100; CPSM, 1: 100; FABPL, 1: 300; OAT, 1: 100; AOFA, 1: 200. The sections were 218 
incubated overnight at 4°C with one of the primary antibodies. After blocking of 219 
endogenous peroxidase by methanol containing 0.3% hydrogen peroxidase, 220 
labeled antigens were detected with an EnVision+ kit (Dako, Glostrup, Denmark) 221 
and visualized employing 3,3’-diaminobenzidine tetrahydrochloride as a 222 
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chromogen. Sections were counterstained with hematoxylin. Appropriate positive 223 
and negative tissue controls were used throughout, in part with reference to the 224 
Human Protein Atlas (URL: http://www.proteinatlas.org/). 225 
   After completely reviewing all slides of immunostained sections for each 226 
sample, I and a pathologist classified cases into 2 groups: those in which ≥ 10% of 227 
cells were positive for S100P, CEAM5, OLFM4, OAT, CAD17, AOFA, CPSM and/or 228 
K1C20 constituted the positive group, while the negative group was comprised 229 
those in which < 10% of cells were positive. For MUC5A and FABPL, those with 230 
strong and moderate immunoreactivity were categorized as the positive group, 231 
while those with absent or weak staining constituted the negative group. Fisher’s 232 
exact test was used to assess the significance of differences among staining 233 
patterns. Differences with P < 0.05 were considered significant. Analyses were 234 
performed with JMP software version 9.0 (SAS Institute, NC, USA).  235 
12 
 
Results 236 
Proteome profiles identified by shotgun proteomics and semi-quantitative 237 
comparison 238 
A discovery set of 21 samples (14 EHCCs, 7 non-cancerous bile ducts) was used to 239 
identify proteins showing different expressions in cancerous and non-cancerous 240 
tissues. Figure 2A is a Venn map for the identified proteins (P < 0.05). I identified 241 
1,266 proteins in stage I EHCC, 1,143 in stage IV EHCC and 1,095 in 242 
non-cancerous bile ducts. In total, 1,992 proteins were identified. The identified 243 
proteins were compared semi-quantitatively using spectral counting. For proteins 244 
identified in non-cancerous bile ducts and EHCC (stages I and IV), Figure 2B 245 
shows a plot of each Rsc value against the corresponding protein (X-axis) in 246 
increasing order from left to right. A positive value indicates greater expression in 247 
EHCC than non-cancerous bile ducts. Proteins with Rsc ≥ 1 and showing a 248 
significant difference by G-test were regarded as candidates for characterization 249 
of EHCC. A total of 136 of the 1,992 proteins identified had P < 0.05, indicating 250 
statistically significant overexpression (Table 1). Housekeeping proteins (ACTB 251 
and glyceraldehyde-3-phosphate dehydrogenase) were commonly expressed in 252 
cancerous and non-cancerous cells with minimum variation by semi-quantitative 253 
comparison.  254 
   The average number of identified proteins per sample was 427. Concerning the 255 
storage period of FFPE tissues, there was no significant difference between old 256 
and recent samples. The average number was 420 in old samples (between 1999 257 
and 2004; n = 10), and was 433 in recent samples (between 2004 and 2008; n = 11).  258 
Quantitative verification by SRM-based targeted proteomics 259 
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SRM measurements were carried out for the discovery set to verify the spectral 260 
counting results. Preliminary analysis of the project control (mixtures of equal 261 
aliquots of all patient samples) was conducted to select readily detectable SRM 262 
transitions and to confirm the retention time of each peptide. Finally, an SRM 263 
assay, comprising 57 proteins (104 peptides, 408 transitions), with sufficient 264 
sensitivity was developed (Table 2). The 57 proteins were 49 found to be 265 
overexpressed by shotgun analysis, 7 previously reported as potential biomarkers 266 
(apolipoprotein A-I, actinin-1, actinin-4, solute carrier family 2 member 1, 267 
fibronectin, keratin type I cytoskeletal 19, and deleted in malignant brain tumors 268 
1),34-36, 40-45 and ACTB (ISIS). 269 
SRM quantitative analysis revealed that 11 proteins, S100P, CEAM5, MUC5A, 270 
OLFM4, OAT, CAD17, FABPL, AOFA, K1C20, CPSM and HMCS2, out of the 57 271 
were overexpressed by at least 2-fold and thus potentially useful for detection of 272 
EHCC (Table 3). Figure 3 is a scatter plot for the normalized peak area. 273 
Meanwhile, the 7 potential biomarkers previously reported were not 274 
overexpressed in my SRM analysis. These results are consistent with those of 275 
spectral counting. 276 
Validation by immunohistochemical analysis 277 
The ten overexpressed proteins were further validated by immunohistochemical 278 
analysis using a validation set of 165 samples. HMCS2 was excluded because no 279 
appropriate antibody was commercially available. I confirmed the specific 280 
expressions of proteins identified by MS analyses (Figure 4). Table 4 shows the 281 
positive rate for each protein in the non-cancerous bile ducts and EHCC. All 282 
non-cancerous bile duct samples were classified into the negative group in 283 
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evaluation of each protein except for 1 sample with positive immunoreactivity for 284 
OAT. However, the positive rates of S100P (84%), CEAM5 (75%), MUC5A (62%), 285 
OLFM4 (60%), OAT (42%), CAD17 (41%), FABPL (38%), AOFA (30%) and K1C20 286 
(25%) differed significantly between non-cancerous bile ducts and EHCC (P < 287 
0.05). CPSM (22%) tended to have a higher positive rate but the difference did not 288 
reach statistical significance (P = 0.07). Only three (2%) EHCC samples were 289 
negative for all proteins.  290 
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Discussion 291 
I identified novel proteins overexpressed in EHCC employing shotgun proteomics 292 
with spectral counting and targeted proteomics based on sSRM. I then validated 293 
my findings immunohistochemically. Shotgun and targeted proteomics revealed 294 
11 proteins to be overexpressed in EHCC as compared with non-cancerous bile 295 
ducts. I immunohistochemically analyzed 10 of these 11 proteins. The 296 
overexpressions of S100P, CEAM5, MUC5A, OLFM4, OAT, CAD17, FABPL, AOFA 297 
and K1C20 in EHCC tissues were confirmed to differ significantly using a 298 
validation set of 165 samples. CPSM tended to be overexpressed in EHCC (P = 299 
0.07). OLFM4, OAT, CAD17, FABPL, AOFA and CPSM were newly discovered to 300 
be associated with EHCC. 301 
OLFM4, a member of the olfactomedin domain-containing family of proteins, is 302 
an anti-apoptotic factor promoting tumor growth.46 OLFM4 promotes pancreatic 303 
cancer cell proliferation by favoring transition from S to G2/M phase,47 and 304 
facilitates cell adhesion.48 OLFM4 expression is related to differentiation and 305 
progression of gastric and colon cancers.49, 50 OLFM4 was expressed in 60% of 306 
EHCC samples, while non-cancerous bile ducts showed no immunoreactivity for 307 
this protein. 308 
OAT is a key enzyme in the pathway converting arginine and ornithine into 309 
the major excitatory and inhibitory neurotransmitters glutamate and 310 
gamma-aminobutyric acid. Although Miyasaka et al demonstrated OAT 311 
overexpression in hepatocellular carcinoma using the suppression subtractive 312 
hybridization technique, little is known about the role of OAT in carcinogenesis.51 313 
CAD17, a cadherin superfamily member, is an important cell adhesion 314 
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molecule and plays major roles in organ development and maintenance of tissue 315 
integrity. A low CAD17 level is associated with a poor prognosis in gastric cancer 316 
and intrahepatic cholangiocarcinoma,52, 53 although the relationship between 317 
CAD17 expression and prognosis in gastric cancer is controversial.54 318 
FABPL is a family of small, highly conserved, cytoplasmic proteins that bind 319 
free fatty acids, and is considered to play roles in fatty acid uptake, transport and 320 
metabolism.55 However, precise roles of FABPL have yet to be elucidated. Several 321 
reports suggest associations of FABPL with colon, gastric and pancreatic 322 
cancers.56-58 323 
AOFA is a mitochondrial enzyme that degrades amine neurotransmitters, 324 
including dopamine, norepinephrine and serotonin.59 Little is known about AOFA 325 
functions in cancer. AOFA is reportedly overexpressed in poorly as compared to 326 
well differentiated prostate cancer, suggesting roles in progression and 327 
aggressiveness of tumors.60 Rybaczyk et al reported significant AOFA 328 
under-expression in several types of cancer,61 but its expression in EHCC has not 329 
been described. 330 
CPSM, expressed mainly in intestinal epithelial and liver cells, is a 331 
mitochondrial enzyme catalyzing the synthesis of carbamoyl phosphate from 332 
ammonia and bicarbonate, and is important for excess urea removal from cells. 333 
Previous reports have shown CPSM overexpression in gastric cancer,62 and 334 
under-expression in human hepatocellular carcinoma.63 Brentnall et al identified 335 
CPSM overexpression in ulcerative colitis patients with high-grade dysplasia or 336 
cancer, as compared to those without dysplasia, by MS analysis.64 337 
S100P, CEAM5, MUC5A and K1C20 are reportedly associated with EHCC. 338 
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Most recently, Hamada et al demonstrated S100P to be a potentially novel 339 
biomarker of EHCC, and noted that detecting S100P expression levels in brushing 340 
cytology had diagnostic value.65 CEAM5, which is identical to clinically-used CEA, 341 
is a cell surface glycoprotein playing roles in cell adhesion and intracellular 342 
signaling.66 Minato et al reported CEAM5 to be expressed in 79% of 343 
cholangiocarcinomas by immunohistochemistry, similar to my findings (75%).67 344 
MUC5A expression was significantly associated with advanced tumors in EHCC, 345 
and the positive rate in EHCC (71%) was significantly higher than that in 346 
intrahepatic cholangiocarcinoma (47%).68 Multivariate analysis of 179 serum 347 
samples obtained pre-operatively from cholangiocarcinoma patients demonstrated 348 
MUC5A positive patients to have a 2.5-fold higher risk of death (P < 0.001).69 349 
K1C20 immunoreactivity in combination with cytokeratin 7 is generally 350 
considered to be valuable for determining the specific origin of an undifferentiated 351 
carcinoma.70, 71  352 
These proteins were analyzed using the Gene Ontology database. The terms 353 
biological processes were explored. OLFM4, CAD17, S100P, CEAM5, MUC5A and 354 
K1C20 were involved in cell migration, adhesion and apoptotic process. On the 355 
other hand, OAT, FABPL, AOFA and CPSM were associated with metabolism. By 356 
analysis using Ingenuity Pathway Analysis, however, protein-protein interactions 357 
among each protein were not observed.  358 
   Few reports have described MS-based proteomics analysis on EHCC using 359 
tissue,35 bile72, 73 and serum samples.36 Compared with those studies, the 360 
outstanding feature of this investigation is that I analyzed actual EHCC tissue 361 
samples, because the etiopathogenesis of EHCC and intrahepatic 362 
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cholangiocarcinoma may differ.74 Kawase et al conducted MS-based proteomic 363 
analysis using 6 paired cancerous, including intrahepatic cholangiocarcinoma and 364 
EHCC, and non-cancerous bile duct cases.35 The overexpressed proteins in their 365 
study, e.g. actinin-1 and actinin-4, were not confirmed by SRM analysis in my 366 
samples. Meanwhile, I obtained samples utilizing LMD technology to isolate 367 
cancerous cells of interest from abundant stroma containing inflammatory cells 368 
and fibroblasts which might hinder identification of cancer-specific proteins. 369 
Using archived FFPE tissues, I analyzed a large number of EHCC samples 370 
including some early stage cases, though opportunities to obtain early stage 371 
EHCC are limited because the diagnosis is usually delayed.  372 
Proliferation of fibrous stroma is a common pathological feature of EHCC. 373 
Using LMD to isolate cancerous cells of interest reduced the complexity of the 374 
subsequent MS analysis for identifying biomarker candidates. Herein, I had an 375 
interest in the proteomes of cancerous cells themselves. LMD presumably 376 
contributed to the observed correlation between the quantitative value and 377 
immunoreactivity. I identified proteins showing different expressions in FFPE 378 
tissues of EHCC and non-cancerous bile ducts, as previously reported for other 379 
malignancies.24-26, 28 380 
Discoveries of novel biomarkers are based on identification of proteins with 381 
expressions that differ between disease and control samples. Global shotgun 382 
proteomics has advantages in terms of the number of proteins identified. With 383 
this approach, the proteomes of complex mixtures can be analyzed in a completely 384 
unbiased fashion with broad proteome coverage, thereby increasing chances to 385 
discover novel biomarkers. Meanwhile, shotgun proteomics tends to be largely 386 
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qualitative rather than quantitative.75 A quantitative approach in global shotgun 387 
analysis is needed to detect proteins showing different expressions in cancerous 388 
and non-cancerous tissues. Spectral counting is one of many semi-quantitative 389 
comparison methods. It has long been recognized that, in the analysis of complex 390 
mixtures, proteins of higher abundance are identified by their more numerous 391 
peptides than low abundance proteins, and that small proteins tend to have fewer 392 
identifiable peptides per protein than large proteins.16 I applied Rsc to detect 393 
proteins with different expression levels, and applied the G-test of independence 394 
to detect significant changes in protein abundance. 395 
Because comparisons of global proteome profiles yield hundreds of candidate 396 
biomarkers, a rational approach to their prioritization before large scale 397 
validation is needed. Verifications of hundreds of candidates by affinity-based 398 
methods, the broadly used Western blot or ELISA approaches, are impractical, 399 
because development of reagents of suitable specificity and affinity to support 400 
accurate detection and quantitation of target proteins remains challenging, 401 
expensive and time consuming. Furthermore, such methods are also hindered by 402 
marked limitations in abilities to detect multiple proteins in the same sample. 403 
High throughput multiplexed assays must be developed to screen and verify 404 
numerous biomarker candidates identified by shotgun analysis. Recently, there 405 
has been great interest in developing MS based verification approaches. 406 
Quantification assays based on SRM MS have been extensively investigated for 407 
protein verification purposes. Specificity is imparted by the SRM technique, 408 
during which peptide ions of interest are monitored based on both the precursor 409 
and resulting product ions after fragmentation. This technique provides two 410 
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significant advantages: biomarker candidates can be assessed simultaneously at 411 
high speed with good quantitative accuracy for verification. I have conducted 412 
MS-based verification using the leading-edge sSRM method.76, 77 sSRM allows 413 
intelligent use of the retention time during an SRM analysis based on the 414 
principle of monitoring SRM transitions only when necessary, while the time 415 
available is already divided into all of the transitions in the classic SRM mode. 416 
Based on retention times, the sSRM method decreases the number of concurrent 417 
SRM transitions monitored at any one time-point, offering improved 418 
reproducibility and signal-to-noise ratio.77 Herein, I detected and quantified 57 419 
proteins and 408 SRM transitions simultaneously in complex mixtures. 420 
Furthermore, this is the first sSRM-based MS analysis in the field of biomarker 421 
discovery.  422 
There is great variability of quantitative values within the group, and 423 
overlapping values between the groups are observed. However, the quantitative 424 
capability of sSRM is confirmed as mentioned above. The intragroup variations 425 
are assumed to be due to the heterogeneity of cancerous tissues themselves. 426 
Therefore, these results suggest that the comparison of proteome profiles of small 427 
number of samples (e.g. 2 samples each) is insufficient and tends to contain 428 
errors.  429 
In sSRM analysis, 7 proteins previously reported as potential biomarker were 430 
added to the sSRM list and quantified for verification. These proteins were not 431 
overexpressed both in shotgun analysis and in sSRM analysis as a result, 432 
suggesting that spectral counting method had a certain quantitative accuracy 433 
compared with sSRM analysis. There are several reasons why those proteins 434 
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showed no overexpression in EHCC in my analyses. The design of previous 435 
studies differed from that of this study in some ways. I compared proteome 436 
profiles of EHCC and non-cancerous bile duct, meanwhile some studies compared 437 
those of EHCC and hepatocellular carcinoma or normal hepatocyte. That is, 438 
targets for comparison were different. Besides, several proteins were detected in 439 
transcriptome analysis, the results of which may differ from that of proteome 440 
analysis. And several proteins were selected by comparisons of smaller number of 441 
samples (e.g. 2 samples each) than this study. Further investigation is needed.  442 
   The newly-identified biomarkers of EHCC in my study are OLFM4, OAT, 443 
CAD17, FABPL, AOFA and CPSM. Additionally, I identified previously reported 444 
biomarkers (S100P, CEAM5, MUC5A and K1C20) in an unbiased fashion, 445 
suggesting my workflow to be extremely useful for biomarker research in a 446 
high-throughput setting. These 10 proteins may improve diagnostic capability 447 
and thus have clinical utility. According to previous reports, the sensitivity of 448 
diagnostic methods such as brushing cytology during endoscopic retrograde 449 
cholangiopancreatography is approximately 60%.78, 79 Applying 450 
immunohistochemistry of these proteins to samples such as those obtained by 451 
brushing cytology or forceps biopsy, might facilitate EHCC diagnosis. Detections 452 
of OLFM4, FABPL, S100P, CEAM5 and MUC5A in serum have been reported. 453 
Thus, it would be reasonable to consider measurements of serum and bile. In the 454 
future, it might be possible to diagnose EHCC by measuring these proteins 455 
simultaneously using SRM-based MS. 456 
In conclusion, I identified several unique proteins, newly discovered to be 457 
associated with EHCC, using MS-based proteomics approaches with archived 458 
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FFPE tissues. These proteins are potential targets for future diagnostic 459 
biomarkers and therapy. These newly discovered proteins are anticipated to 460 
facilitate unraveling of the molecular events that underlie this lethal disease. 461 
Many of these proteins are poorly-documented, and their roles in EHCC merit 462 
further investigation.   463 
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Figure legends 711 
Figure 1. Study design for identification and validation of novel biomarkers of 712 
EHCC. Shotgun proteomics with semi-quantitative spectral counting was 713 
conducted to identify proteins with expression profiles differing between EHCC 714 
and non-cancerous bile ducts. Selected candidates were verified by quantitative 715 
analysis using scheduled SRM-based targeted proteomics. The resulting proteins 716 
were then validated by immunohistochemical analysis. 717 
 718 
Figure 2A. Venn map of proteins identified from 14 EHCC and 7 non-cancerous 719 
bile ducts. Shotgun proteomics identified 1,992 unique proteins. 720 
 721 
Figure 2B. Rsc and NSAF values calculated for the proteins identified (X-axis). 722 
Protein expressions are compared between EHCC and non-cancerous bile ducts. 723 
Proteins significantly overexpressed in EHCC are near the right side of the X-axis. 724 
ACTB is located near the center of the X-axis. 725 
 726 
Figure 3. Scatter plot of the normalized peak area by SRM-based quantitative 727 
analysis. Proteins overexpressed by at least 2-fold in stage I and/or stage IV 728 
EHCC are shown. 729 
 730 
Figure 4. Representative immunohistochemical staining results for the indicated 731 
proteins in EHCC and non-cancerous bile ducts. Sections of non-cancerous bile 732 
ducts were obtained from patients without EHCC. Positive staining is shown in 733 
brown. Scale bars represent 100 µm.  734 
Table 1. Overexpressed proteins identified by global shotgun proteomics. 
AC ID Protein name 
Spectral counting G-test 
No. of peptides 
Fold 
change 
(Rsc) 
P-value 
Non-cancerous 
Bile duct 
EHCC 
P31327 CPSM_HUMAN Carbamoyl-phosphate synthase [ammonia], mitochondrial  0 120 5.581  < 0.001  
P05141 ADT2_HUMAN ADP/ATP translocase 2 0 74 4.890  < 0.001 
Q71U36 TBA1A_HUMAN Tubulin alpha-1A chain 0 58 4.545  < 0.001 
P21397 AOFA_HUMAN Amine oxidase [flavin-containing] A 0 35 3.835  < 0.001 
P02538 K2C6A_HUMAN Keratin, type II cytoskeletal 6A 0 35 3.835  < 0.001 
P54868 HMCS2_HUMAN Hydroxymethylglutaryl-CoA synthase, mitochondrial  0 31 3.666  < 0.001  
P13645 K1C10_HUMAN Keratin, type I cytoskeletal 10 0 29 3.573  < 0.001 
P31930 QCR1_HUMAN Cytochrome b-c1 complex subunit 1, mitochondrial  0 25 3.369  < 0.001  
Q01105 SET_HUMAN Protein SET 0 23 3.254  < 0.001 
P13647 K2C5_HUMAN Keratin, type II cytoskeletal 5 0 23 3.254  < 0.001 
P01892 1A02_HUMAN HLA class I histocompatibility antigen, A-2 alpha chain  0 22 3.193  < 0.001  
P10316 1A69_HUMAN HLA class I histocompatibility antigen, A-69 alpha 0 22 3.193  < 0.001 
P31937 3HIDH_HUMAN 3-hydroxyisobutyrate dehydrogenase, mitochondrial  0 20 3.063  < 0.001 
P48735 IDHP_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial  3 70 3.046  < 0.001  
Q15063 POSTN_HUMAN Periostin  0 18 2.921  < 0.001 
Q9BVA1 TBB2B_HUMAN Tubulin beta-2B chain 0 18 2.921  < 0.001 
P54886 P5CS_HUMAN Delta-1-pyrroline-5-carboxylate synthetase 0 17 2.844  < 0.001 
P15144 AMPN_HUMAN Aminopeptidase N 0 17 2.844  < 0.001 
Q08380 LG3BP_HUMAN Galectin-3-binding protein  0 16 2.762  < 0.001 
O75369 FLNB_HUMAN Filamin-B 5 81 2.697  < 0.001 
Q13263 TIF1B_HUMAN Transcription intermediary factor 1-beta 0 15 2.676  < 0.001 
Q92597 NDRG1_HUMAN Protein NDRG1 0 15 2.676  < 0.001 
P07602 SAP_HUMAN Proactivator polypeptide [Contains: Saposin-A 0 14 2.585  0.001  
P30443 1A01_HUMAN HLA class I histocompatibility antigen, A-1 alpha chain  0 13 2.487  0.002  
P34897 GLYM_HUMAN Serine hydroxymethyltransferase, mitochondrial  0 13 2.487  0.002  
P07148 FABPL_HUMAN Fatty acid-binding protein, liver 0 13 2.487  0.002  
P99999 CYC_HUMAN Cytochrome c 0 13 2.487  0.002  
P07384 CAN1_HUMAN Calpain-1 catalytic subunit 0 13 2.487  0.002  
P06396 GELS_HUMAN Gelsolin  2 34 2.416  < 0.001   
Q12931 TRAP1_HUMAN Heat shock protein 75 kDa, mitochondrial  0 12 2.382  0.003  
P09622 DLDH_HUMAN Dihydrolipoyl dehydrogenase, mitochondrial  0 12 2.382  0.003  
P0C7M2 RA1L3_HUMAN 
Putative heterogeneous nuclear ribonucleoprotein A1-like 
protein 3 
0 12 2.382  0.003  
Q04837 SSB_HUMAN Single-stranded DNA-binding protein, mitochondrial  0 12 2.382  0.003  
P24752 THIL_HUMAN Acetyl-CoA acetyltransferase, mitochondrial  1 22 2.345  < 0.001  
P06753 TPM3_HUMAN Tropomyosin alpha-3 chain 2 32 2.331  < 0.001  
P42704 LPPRC_HUMAN Leucine-rich PPR motif-containing protein, mitochondrial  1 21 2.282  0.001 
P50991 TCPD_HUMAN T-complex protein 1 subunit delta 0 11 2.268  0.004  
P18465  1B57_HUMAN HLA class I histocompatibility antigen, B-57 alpha chain  0 11 2.268  0.004  
P30462 1B14_HUMAN HLA class I histocompatibility antigen, B-14 alpha chain  0 11 2.268  0.004  
Q9Y2X3 NOL5_HUMAN Nucleolar protein 5 0 11 2.268  0.004  
Q06323 PSME1_HUMAN Proteasome activator complex subunit 1 1 20 2.215  0.002  
Q9BQE3 TBA1C_HUMAN Tubulin alpha-1C chain 20 196 2.197  < 0.001  
P00352 AL1A1_HUMAN Retinal dehydrogenase 1 6 64 2.145  < 0.001  
O43399 TPD54_HUMAN Tumor protein D54 1 19 2.146  0.002  
Q6XQN6  PNCB_HUMAN Nicotinate phosphoribosyltransferase 1 19 2.146  0.002  
P20962 PTMS_HUMAN Parathymosin 0 10 2.145  0.006  
Q6UX06 OLFM4_HUMAN Olfactomedin-4  0 10 2.145  0.006  
Q96C19 EFHD2_HUMAN EF-hand domain-containing protein D2 0 10 2.145  0.006  
Q01995 TAGL_HUMAN Transgelin 0 10 2.145  0.006  
P52895 AK1C2_HUMAN Aldo-keto reductase family 1 member C2 0 10 2.145  0.006  
P21333 FLNA_HUMAN Filamin-A 3 36 2.108  < 0.001  
P01009 A1AT_HUMAN Alpha-1-antitrypsin  5 52 2.068  < 0.001  
P12236 ADT3_HUMAN ADP/ATP translocase 3 4 43 2.052  < 0.001  
P05451 REG1A_HUMAN Lithostathine-1-alpha  0 9 2.011  0.009  
P02792  FRIL_HUMAN Ferritin light chain 0 9 2.011  0.009  
Q9UBQ7 GRHPR_HUMAN Glyoxylate reductase/hydroxypyruvate reductase 0 9 2.011  0.009  
P30046 DOPD_HUMAN D-dopachrome decarboxylase 0 9 2.011  0.009 
Q9UD71 PPR1B_HUMAN Protein phosphatase 1 regulatory subunit 1B 0 9 2.011  0.009  
P04181 OAT_HUMAN Ornithine aminotransferase, mitochondrial  0 9 2.011  0.009  
P30685 1B35_HUMAN HLA class I histocompatibility antigen, B-35 alpha chain  0 9 2.011  0.009  
P40199 CEAM6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6  0 9 2.011  0.009  
P35527 K1C9_HUMAN Keratin, type I cytoskeletal 9 0 9 2.011  0.009  
P06731 CEAM5_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5  0 9 2.011  0.009  
P18464 1B51_HUMAN HLA class I histocompatibility antigen, B-51 alpha chain  0 9 2.011  0.009  
P28838 AMPL_HUMAN Cytosol aminopeptidase 2 25 1.990  0.002  
P49327 FAS_HUMAN Fatty acid synthase 4 41 1.985  < 0.001  
P20142 PEPC_HUMAN Gastricsin  0 8 1.863  0.015  
O60506  HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q 0 8 1.863 0.015  
Q96HR9 REEP6_HUMAN Receptor expression-enhancing protein 6 0 8 1.863  0.015 
P55327 TPD52_HUMAN Tumor protein D52 0 8 1.863  0.015 
P39687 AN32A_HUMAN 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member A 
0 8 1.863  0.015 
P84085 ARF5_HUMAN ADP-ribosylation factor 5 0 8 1.863  0.015  
P25815 S100P_HUMAN Protein S100-P 2 22 1.815  0.005  
P02787 TRFE_HUMAN Serotransferrin  3 29 1.808  0.002  
P22314 UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 4 36 1.803  < 0.001  
Q3LXA3 DHAK_HUMAN Dihydroxyacetone kinase 4 36 1.803  < 0.001  
Q99497 PARK7_HUMAN Protein DJ-1 1 14 1.736  0.016  
Q9NX63 CHCH3_HUMAN 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial  
1 14 1.736  0.016 
Q9H4A4 AMPB_HUMAN Aminopeptidase B 0 7 1.698  0.023  
P0C0S5  H2AZ_HUMAN Histone H2A.Z 0 7 1.698  0.023  
P05455 LA_HUMAN Lupus La protein 0 7 1.698  0.023  
P08708 RS17_HUMAN 40S ribosomal protein S17 0 7 1.698  0.023  
P50440 GATM_HUMAN Glycine amidinotransferase, mitochondrial  0 7 1.698  0.023  
P30041 PRDX6_HUMAN Peroxiredoxin-6 - 0 7 1.698  0.023  
Q9BUF5 TBB6_HUMAN Tubulin beta-6 chain 0 7 1.698  0.023  
P29590 PML_HUMAN Probable transcription factor PML 0 7 1.698  0.023  
P21796 VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 6 46 1.681  < 0.001  
Q7Z406 MYH14_HUMAN Myosin-14 40 266 1.680  < 0.001  
Q13185 CBX3_HUMAN Chromobox protein homolog 3 1 13 1.639  0.023  
P98088 MUC5A_HUMAN Mucin-5AC  1 13 1.639  0.023  
P42224 STAT1_HUMAN 
Signal transducer and activator of transcription 
1-alpha/beta 
2 19 1.615  0.012  
O43488 ARK72_HUMAN Aflatoxin B1 aldehyde reductase member 2 2 19 1.615  0.012  
P40939 ECHA_HUMAN Trifunctional enzyme subunit alpha, mitochondrial  5 36 1.552  0.002  
P35232 PHB_HUMAN Prohibitin 4 30 1.550  0.004  
P35237 SPB6_HUMAN Serpin B6 1 12 1.534  0.033  
Q07955 SFRS1_HUMAN Splicing factor, arginine/serine-rich 1 1 12 1.534  0.033  
P35900 K1C20_HUMAN Keratin, type I cytoskeletal 20 6 41 1.5193  0.002  
Q92522 H1X_HUMAN Histone H1x  0 6 1.5113  0.037  
P46934 NEDD4_HUMAN E3 ubiquitin-protein ligase NEDD4 0 6 1.5113  0.037  
P40925 MDHC_HUMAN Malate dehydrogenase, cytoplasmic 0 6 1.5113  0.037  
P50454 SERPH_HUMAN Serpin H1  0 6 1.5113  0.037  
Q99729 ROAA_HUMAN Heterogeneous nuclear ribonucleoprotein A/B 0 6 1.5113  0.037  
Q12864 CAD17_HUMAN Cadherin-17  0 6 1.5113  0.037  
Q92616 GCN1L_HUMAN Translational activator GCN1 0 6 1.5113  0.037  
Q86V81 THOC4_HUMAN THO complex subunit 4 0 6 1.5113  0.037  
Q16822  PPCKM_HUMAN Phosphoenolpyruvate carboxykinase [GTP], mitochondrial  0 6 1.5113  0.037  
Q9ULC5 ACSL5_HUMAN Long-chain-fatty-acid--CoA ligase 5 0 6 1.5113  0.037  
Q9BUL8 PDC10_HUMAN Programmed cell death protein 10 0 6 1.5113  0.037  
Q96AC1 FERM2_HUMAN Fermitin family homolog 2 0 6 1.5113  0.037  
P62834 RAP1A_HUMAN Ras-related protein Rap-1A  0 6 1.5113  0.037  
P16190 1A33_HUMAN HLA class I histocompatibility antigen, A-33 alpha chain  0 6 1.511  0.037  
Q9NZM1 MYOF_HUMAN Myoferlin 0 6 1.511  0.037  
Q6NZI2 PTRF_HUMAN Polymerase I and transcript release factor 0 6 1.511  0.037  
P55795 HNRH2_HUMAN Heterogeneous nuclear ribonucleoprotein H2 0 6 1.511  0.037  
P22392 NDKB_HUMAN Nucleoside diphosphate kinase B 0 6 1.511  0.037  
P84243 H33_HUMAN Histone H3.3 4 29 1.503  0.006  
Q96I99 SUCB2_HUMAN 
Succinyl-CoA ligase [GDP-forming] subunit beta, 
mitochondrial  
1 11 1.420  0.047  
P00480 OTC_HUMAN Ornithine carbamoyltransferase, mitochondrial  1 11 1.420  0.047  
Q6P996 PDXD1_HUMAN 
Pyridoxal-dependent decarboxylase domain-containing 
protein 1 
1 11 1.420  0.047  
P40926  MDHM_HUMAN Malate dehydrogenase, mitochondrial  19 106 1.383  < 0.001  
O00264 PGRC1_HUMAN Membrane-associated progesterone receptor component 1 3 21 1.364  0.022 
Q16891 IMMT_HUMAN Mitochondrial inner membrane protein 3 21 1.364  0.022  
Q01518 CAP1_HUMAN Adenylyl cyclase-associated protein 1 5 31 1.343  0.009  
P09327 VILI_HUMAN Villin-1 6 35 1.298  0.008  
P30084 ECHM_HUMAN Enoyl-CoA hydratase, mitochondrial  4 25 1.298  0.019  
P51149 RAB7A_HUMAN Ras-related protein Rab-7a 3 19 1.228  0.040  
P19971 TYPH_HUMAN Thymidine phosphorylase  9 47 1.211  0.004  
P16219 ACADS_HUMAN 
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
4 23 1.183  0.034  
Q99623 PHB2_HUMAN Prohibitin-2 11 55 1.176  0.003  
Q9Y490 TLN1_HUMAN Talin-1 9 45 1.150  0.007  
P38159 HNRPG_HUMAN Heterogeneous nuclear ribonucleoprotein G 4 22 1.123  0.044  
P25325 THTM_HUMAN 3-mercaptopyruvate sulfurtransferase 4 22 1.123  0.044  
P30086 PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 5 26 1.100  0.036  
P04264 K2C1_HUMAN Keratin, type II cytoskeletal 1 9 42 1.0532  0.015  
P23528 COF1_HUMAN Cofilin-1 14 63 1.0516  0.004  
P35222 CTNB1_HUMAN Catenin beta-1 5 25 1.0461  0.046  
EHCC, extrahepatic cholangiocarcinoma; Rsc, protein ratio from spectral counting. 
Table 2. Proteins to which the scheduled SRM MS analysis was applied. 
No. ID Protein name 
SRM 
Spectral 
counting 
G-test 
No. of  
peptides 
No. of  
transitions 
Fold 
change 
(Rsc) 
P-value 
1 CPSM_HUMAN 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial  
5 20 5.581 < 0.001  
2 AOFA_HUMAN Amine oxidase [flavin-containing] A  1 4 3.835 < 0.001  
3 HMCS2_HUMAN Hydroxymethylglutaryl-CoA synthase, mitochondrial  2 8 3.666 < 0.001  
4 QCR1_HUMAN Cytochrome b-c1 complex subunit 1, mitochondrial  1 4 3.369 < 0.001  
5 SET_HUMAN Protein SET 1 4 3.254 < 0.001  
6 LG3BP_HUMAN Galectin-3-binding protein  1 4 2.762 < 0.001  
7 FLNB_HUMAN Filamin-B 3 12 2.697 < 0.001  
8 TIF1B_HUMAN Transcription intermediary factor 1-beta 2 7 2.676 < 0.001  
9 FABPL_HUMAN Fatty acid-binding protein, liver 1 4 2.487 0.002 
10 CYC_HUMAN Cytochrome c 1 4 2.487 0.002 
11 GELS_HUMAN Gelsolin  1 4 2.416 < 0.001  
12 TRAP1_HUMAN Heat shock protein 75 kDa, mitochondrial  1 3 2.382 0.003 
13 LPPRC_HUMAN 
Leucine-rich PPR motif-containing protein, 
mitochondrial  
1 4 2.282 < 0.001  
14 PSME1_HUMAN Proteasome activator complex subunit 1 2 8 2.215 0.002 
15 AL1A1_HUMAN Retinal dehydrogenase 1  2 8 2.148 < 0.001  
16 TPD54_HUMAN Tumor protein D54 1 4 2.146 0.002 
17 EFHD2_HUMAN EF-hand domain-containing protein D2 1 4 2.145 0.006 
18 OLFM4_HUMAN Olfactomedin-4  3 12 2.145 0.006 
19 FLNA_HUMAN Filamin-A 2 8 2.108 < 0.001  
20 A1AT_HUMAN Alpha-1-antitrypsin  3 12 2.068 < 0.001  
21 ADT3_HUMAN ADP/ATP translocase 3  2 8 2.052 < 0.001  
22 OAT_HUMAN Ornithine aminotransferase, mitochondrial  2 8 2.011 0.009 
23 CEAM6_HUMAN 
Carcinoembryonic antigen-related cell adhesion 
molecule 6  
1 4 2.011 0.009 
24 CEAM5_HUMAN 
Carcinoembryonic antigen-related cell adhesion 
molecule 5  
1 4 2.011 0.009 
25 AMPL_HUMAN Cytosol aminopeptidase  1 4 1.99 0.002 
26 FAS_HUMAN Fatty acid synthase  2 8 1.985 < 0.001  
27 TPD52_HUMAN Tumor protein D52 2 8 1.863 0.015 
28 PEPC_HUMAN Gastricsin  2 7 1.863 0.015 
29 S100P_HUMAN Protein S100-P  1 4 1.815 0.005 
30 TRFE_HUMAN Serotransferrin  2 7 1.808 0.002 
31 PRDX6_HUMAN Peroxiredoxin-6 1 4 1.698 0.023 
32 PML_HUMAN Probable transcription factor PML  1 4 1.698 0.023 
33 VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1  2 8 1.681 < 0.001  
34 MYH14_HUMAN Myosin-14  4 16 1.68 < 0.001  
35 MUC5A_HUMAN Mucin-5AC  1 4 1.638 0.023 
36 ARK72_HUMAN Aflatoxin B1 aldehyde reductase member 2  1 4 1.615 0.012 
37 STAT1_HUMAN 
Signal transducer and activator of transcription 
1-alpha/beta 
2 8 1.615 0.012 
38 PHB_HUMAN Prohibitin  4 16 1.55 0.004 
39 K1C20_HUMAN Keratin, type I cytoskeletal 20  3 12 1.519 0.002 
40 SERPH_HUMAN Serpin H1  1 4 1.511 0.037 
41 CAD17_HUMAN Cadherin-17  1 4 1.511 0.037 
42 ACSL5_HUMAN Long-chain-fatty-acid--CoA ligase 5  2 8 1.511 0.037 
43 CAP1_HUMAN Adenylyl cyclase-associated protein 1 1 4 1.343 0.009 
44 VILI_HUMAN Villin-1 4 16 1.298 0.008 
45 TYPH_HUMAN Thymidine phosphorylase  1 4 1.211 0.004 
46 PHB2_HUMAN Prohibitin-2  3 11 1.176 0.003 
47 TLN1_HUMAN Talin-1 3 12 1.15 0.007 
48 PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1  2 8 1.1 0.036 
49 CTNB1_HUMAN Catenin beta-1 1 4 1.046 0.046 
50 APOA1_HUMAN Apolipoprotein A-I  1 4 1.046 0.095 
51 ACTN4_HUMAN Alpha-actinin-4  4 15 0.606 0.003 
52 GTR1_HUMAN 
Solute carrier family 2, facilitated glucose transporter 
member 1 
1 3 0.354 0.266 
53 ACTB_HUMAN Actin, cytoplasmic 1 1 4 0.163 0.114 
54 FINC_HUMAN Fibronectin  1 4 -0.068 0.845 
55 ACTN1_HUMAN Alpha-actinin-1 2 8 -0.473 0.049 
56 K1C19_HUMAN Keratin, type I cytoskeletal 19  4 15 -0.61 < 0.001  
57 DMBT1_HUMAN Deleted in malignant brain tumors 1 protein  1 4 -1.426 0.079 
SRM, selected reaction monitoring; Rsc, protein ratio from spectral counting. 
Table 3. List of the candidate proteins by SRM analysis 
 
 
 
    SRM transition Average of normarized peak area Fold change  
AC ID Protein name 
[precursor ion(m/z)/ 
product ion(m/z)] 
JSBS 
stage I 
JSBS 
stage IV 
Non- cancerous 
bile duct 
JSBS stage I/ 
Non-cancerous 
bile duct 
JSBS stage IV/ 
Non-cancerous 
bile duct 
P25815 S100P_Human Protein S100-P 679.8 / 1050.5 1169  2248  592  1.9 3.8 
P06731 CEAM5_Human Carcinoembryonic antigen-related cell adhesion molecule 5 precursor 733.3 / 1051.5 494  5909  235  2.1 25.1 
P98088 MUC5A_Huma
n 
Mucin-5AC precursor 770.3 / 1179.6 293  1146  328  0.9 3.5 
Q6UX06 OLFM4_Human Olfactomedin-4 precursor 872.4 / 1271.6 1762  615  209  8.4 2.9 
P04181 OAT_Human Ornithine aminotransferase, mitochondrial precursor 528.8 / 846.5 10773  3847  3077  3.5  1.3 
Q12864 CAD17_Human Cadherin-17 precursor 885.0 / 1304.7 1313  211  312  4.2 0.7 
P07148 FABPL_Human Fatty acid-binding protein, liver 551.8 / 902.5 9259  10315  741  12.5 13.9 
P21397 AOFA_Human Amine oxidase [flavin-containing] A 593.3 / 778.4 17748  6894  3632  4.9 1.9  
P35900 K1C20_Human Keratin, type I cytoskeletal 20 722.9 / 1115.6 1861  98  165  11.3 0.6 
P31327 CPSM_Human Carbamoyl-phosphate synthase [ammonia], mitochondrial precursor 710.4 / 1249.6 1460  1031 23  62.3 44.0 
P54868 HMCS2_Human Hydroxymethylglutaryl-CoA synthase, mitochondrial precursor 585.8 / 929.5 45269  5956 989  45.8 6.0 
SRM, selected reaction monitoring; JSBS, Japanese Society of Biliary Surgery. 
Table 4. Immunohistochemical findings of the validation set. 
 Non-cancerous 
bile duct 
( n = 14) 
  JSBS 
stage I 
( n = 5) 
JSBS 
stage II 
( n = 37) 
JSBS 
stage III 
( n = 50) 
JSBS 
stage IV 
( n = 59) 
Antibody EHCC 
(n = 151) 
P-value 
S100P 0 (0%) 127 (84%) < 0.01 4 (80%) 32 (86%) 43 (86%) 48 (81%) 
CEAM5 0 (0%) 113 (75%) < 0.01 1 (20%) 29 (78%) 39 (78%) 44 (75%) 
MUC5A 0 (0%) 94 (62%) < 0.01 3 (60%) 17 (46%) 35 (75%) 39 (66%) 
OLFM4 0 (0%) 91 (60%) < 0.01 1 (20%) 24 (65%) 28 (56%) 38 (64%) 
OAT 1 (7%) 63 (42%) < 0.01 4 (80%) 16 (43%) 19 (38%) 24 (41%) 
CAD17 0 (0%) 62 (41%) < 0.01 4 (80%) 19 (51%) 22 (44%) 17 (29%) 
FABPL 0 (0%) 57 (38%) < 0.01 2 (40%) 13 (35%) 19 (38%) 23 (39%) 
AOFA 0 (0%) 45 (30%) 0.01 2 (40%) 14 (38%) 11 (22%) 18 (31%) 
K1C20 0 (0%) 38 (25%) 0.04 1 (20%) 8 (22%) 17 (34%) 12 (20%) 
CPSM 0 (0%) 33 (22%) 0.07 1 (20%) 9 (24%) 10 (20%) 13 (22%) 
EHCC, extrahepatic cholangiocarcinoma; JSBS, Japanese Society of Biliary Surgery. 
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